Veracyte Inc (VCYT)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ
Market Cap: $1.96B
Last updated: Nov 17, 2026 at 11:05 AM ET
Veracyte Inc (VCYT) Financials: Revenue, Profit and Cash Flow
Veracyte reported revenue of $517.14M for the fiscal year ended Dec 31, 2025, up 16.0% from the year before. That year, net income was $66.35M with a net margin of 12.8%, operating cash flow was $136.31M and free cash flow was $126.63M. The quarter ended Sep 30, 2026 had revenue of $151.75M and net income of $31.50M.
Revenue and Margins
The operating margin was 11.2% in the fiscal year ended Dec 2025, the highest of the 10 years shown. Over the 9 years to Dec 2025, revenue grew from $65.08M, a compound annual rate of 25.9%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $517.14M | +16.0% | 70.1% | 11.2% | 12.8% |
| Dec 2024 | $445.76M | +23.5% | 66.9% | 3.6% | 5.4% |
| Dec 2023 | $361.05M | +21.8% | 63.6% | -23.8% | -20.6% |
| Dec 2022 | $296.54M | +35.1% | 59.2% | -13.9% | -12.3% |
| Dec 2021 | $219.51M | +86.8% | 66.1% | -37.3% | -34.4% |
| Dec 2020 | $117.48M | -2.4% | 64.7% | -30.1% | -29.7% |
| Dec 2019 | $120.37M | +30.8% | 69.7% | -12.6% | -10.5% |
| Dec 2018 | $92.01M | +27.9% | 64.0% | -24.2% | -25.0% |
| Dec 2017 | $71.95M | +10.6% | 60.8% | -36.9% | -43.1% |
| Dec 2016 | $65.08M | N/A | 60.9% | -44.3% | -48.2% |
Income Statement
In the fiscal year ended Dec 2025, net income rose 174.9% from the year before. In the quarter ended Sep 2026, net income rose 64.6% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $517.14M | $445.76M | $361.05M | $296.54M | $219.51M | $117.48M | $120.37M | $92.01M | $71.95M | $65.08M |
| Cost of revenue | $154.61M | $147.62M | $131.37M | $120.86M | $74.40M | $41.45M | $36.52M | $33.08M | $28.20M | $25.46M |
| Gross profit | $362.53M | $298.14M | $229.68M | $175.68M | $145.11M | $76.03M | $83.84M | $58.93M | $43.76M | $39.62M |
| Research and development | $70.81M | $69.29M | $57.30M | $40.60M | $29.84M | $17.20M | $14.85M | $14.82M | $13.88M | $15.32M |
| Operating income | $57.78M | $16.14M | -$85.80M | -$41.08M | -$81.90M | -$35.39M | -$15.13M | -$22.23M | -$26.54M | -$28.80M |
| Net income | $66.35M | $24.14M | -$74.40M | -$36.56M | -$75.56M | -$34.91M | -$12.60M | -$23.00M | -$31.00M | -$31.36M |
| EBITDA | $86.35M | $48.85M | -$49.89M | -$10.50M | -$62.06M | -$26.96M | -$8.40M | -$17.08M | -$22.23M | -$26.07M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $151.75M | $150.32M | $139.07M | $140.64M | $131.87M | $130.16M | $114.47M | $118.63M | $115.86M | $114.43M | $96.84M | $98.20M |
| Gross profit | $107.10M | $108.55M | $101.16M | $101.97M | $91.28M | $89.77M | $79.51M | $78.75M | $79.01M | $77.91M | $62.47M | $59.98M |
| Operating income | $16.57M | $22.98M | $22.65M | $37.20M | $22.95M | -$5.27M | $2.90M | $4.17M | $12.02M | $4.61M | -$4.66M | -$35.51M |
| Net income | $31.50M | $25.49M | $28.71M | $41.15M | $19.14M | -$980.00K | $7.05M | $5.11M | $15.15M | $5.73M | -$1.86M | -$28.29M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded short-term debt of $1.33M by $361.25M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $1.41B | $1.30B | $1.11B | $1.16B | $1.19B | $457.16M | $275.21M | $120.64M | $78.67M | $101.03M |
| Current assets | $488.38M | $372.27M | $285.62M | $248.64M | $243.10M | $375.68M | $187.69M | $96.95M | $53.93M | $73.63M |
| Cash and equivalents | $362.58M | $239.09M | $216.45M | $154.25M | $173.20M | $349.36M | $159.32M | $78.00M | $33.89M | $59.22M |
| Total liabilities | $96.44M | $124.07M | $70.80M | $81.22M | $91.31M | $35.93M | $35.76M | $40.88M | $41.44M | $41.45M |
| Short-term debt | $1.33M | $16.98M | $2.66M | $6.06M | $3.81M | $0 | $1.41M | $1.36M | $0 | $25.52M |
| Long-term debt | N/A | N/A | N/A | N/A | N/A | $810.00K | $694.00K | $23.93M | $24.94M | $24.92M |
| Shareholder equity | $1.31B | $1.18B | $1.04B | $1.08B | $1.10B | $421.23M | $239.46M | $79.75M | $37.23M | $59.58M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $1.57B | $1.49B | $1.44B | $1.41B | $1.37B | $1.34B | $1.32B | $1.30B | $1.28B | $1.23B | $1.20B | $1.11B |
| Total liabilities | $139.99M | $97.96M | $91.99M | $96.44M | $110.12M | $123.05M | $120.47M | $124.07M | $98.98M | $101.80M | $81.42M | $70.80M |
| Cash and equivalents | $199.83M | $299.52M | $263.14M | $362.58M | $315.57M | $219.50M | $186.12M | $239.09M | $274.08M | $235.91M | $209.19M | $216.45M |
| Shareholder equity | $1.43B | $1.39B | $1.34B | $1.31B | $1.26B | $1.22B | $1.19B | $1.18B | $1.18B | $1.13B | $1.12B | $1.04B |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 92.9% of operating cash flow.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $136.31M | $75.10M | $44.22M | $7.54M | -$31.62M | -$9.71M | -$3.23M | -$13.52M | -$23.91M | -$27.98M |
| Capital expenditures | $9.68M | $11.29M | $9.96M | $8.55M | $5.38M | $2.84M | $2.76M | $1.87M | $1.75M | $4.21M |
| Free cash flow | $126.63M | $63.81M | $34.26M | -$1.01M | -$37.00M | -$12.55M | -$5.99M | -$15.39M | -$25.67M | -$32.19M |
| Dividends paid | N/A | N/A | N/A | $3.17M | N/A | $3.85M | $977.00K | N/A | $0 | $0 |
| Investing cash flow | -$9.21M | -$56.27M | $15.11M | -$29.39M | -$739.21M | -$3.84M | -$42.73M | -$1.87M | -$1.31M | -$4.21M |
| Financing cash flow | -$4.22M | $4.90M | $2.84M | $3.49M | $596.32M | $203.59M | $127.29M | $59.50M | -$218.00K | $52.33M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $40.26M | $45.83M | $35.22M | $52.58M | $44.76M | $33.60M | $5.36M | $24.52M | $29.96M | $29.57M | -$8.97M | $15.55M |
| Capital expenditures | $2.33M | $2.86M | $2.96M | $3.78M | $2.79M | $1.29M | $1.82M | $4.14M | $2.24M | $2.77M | $2.13M | $2.50M |
| Free cash flow | $37.92M | $42.97M | $32.25M | $48.80M | $41.97M | $32.32M | $3.54M | $20.38M | $27.72M | $26.80M | -$11.10M | $13.05M |
Frequently Asked Questions About VCYT
What is Veracyte's annual revenue?
Veracyte reported revenue of $517.14M for the fiscal year ended Dec 31, 2025.
How fast is Veracyte's revenue growing?
Revenue was up 16.0% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 20.4%.
Is Veracyte profitable?
Yes. Veracyte reported net income of $66.35M for the fiscal year ended Dec 31, 2025, with a net margin of 12.8%.
How much free cash flow does VCYT generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $136.31M minus capital expenditures of $9.68M produced free cash flow of $126.63M.
How much debt does Veracyte have?
The balance sheet dated Dec 31, 2025 reported short-term debt of $1.33M and cash and equivalents of $362.58M.
VCYT pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts